Industries > Pharma > Adult Vaccines Market Report to 2031
Adult Vaccines Market Report to 2031
Forecasts By Vaccine (Influenza, Tetanus /Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), By Vaccine Type (Monovalent and Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines) PLUS COVID-19 Recovery Scenarios
Adult Vaccines Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Adult Vaccines is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Adult Vaccines Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Adult Vaccines Market: By Vaccine
• Influenza, Tetanus/Diphtheria/Pertussis
• Varicella
• Human Papillomavirus
• Zoster
• Measles/mumps/Rubella
• Pneumococcal
• Hepatitis
• Others
Adult Vaccines Market: By Vaccine Type
• Monovalent
• Multivalent
Adult Vaccines Market: By Technology
• Live Attenuated Vaccines
• Inactivated Viral or Bacterial Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Conjugate Vaccines
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Adult Vaccines Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Adult Vaccines Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Adult Vaccines Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Adult Vaccines Market, with forecasts for Vaccine, Vaccine Type, and Technology, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Adult Vaccines market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Adult Vaccines Market. Some of the company’s profiled in this report include GlaxoSmithKline Plc, Merck & Co., Sanofi Pasteur, Pfizer, Inc., CSL Limited, and Johnson & Johnson, Serum Institute of India, Medimmune, AstraZeneca Plc., and BioCSL (Seqirus).
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Adult Vaccines Market Report to 2031: Forecasts By Vaccine (Influenza, Tetanus /Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, and Others), By Vaccine Type (Monovalent and Multivalent), By Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, and Conjugate Vaccines) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Adult Vaccines Market
2.1. Adult Vaccines Market Definition
2.2. Vaccine Submarkets Definitions
2.3. Vaccine Type Submarkets Definitions
2.4. Technology Submarkets Definitions
3. Adult Vaccines Market Overview
3.1. Global Adult Vaccines Market Size and Forecast by Region
3.2. Global Adult Vaccines Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. A rise in Cases of Infectious Diseases in the Adults
3.3.1.2. Increase in Government Funding for Research Activities to Develop Vaccines
3.3.1.3. High Prevalence of Infectious Diseases
3.3.1.4. Rising Focus on Immunization Programs
3.3.1.5. Growing Government Support for Vaccine Development
3.3.1.6. Increasing Company Initiatives to Enhance Vaccine R&D
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost of Vaccine Development
3.3.2.2. Inadequate Access to Vaccines
3.3.2.3. Product Recalls
3.3.3. Opportunities
3.3.3.1. High Growth Prospects in Emerging Markets
3.3.3.2. Focus on Therapeutic Vaccines
3.3.3.3. Use of Adjuvants in Vaccines
3.3.4. Global Adult Vaccines Market: Trends
3.3.4.1. Increasing Number of Acquisitions
3.3.4.2. Focus on Expanding Capabilities of Current Technologies and Products
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Adult Vaccines Market Analysis and Forecast 2021-2031, by Vaccine (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Influenza
4.1.2. Tetanus/Diphtheria/Pertussis
4.1.3. Varicella
4.1.4. Human Papillomavirus
4.1.5. Zoster
4.1.6. Measles/Mumps/Rubella
4.1.7. Pneumococcal
4.1.8. Hepatitis
4.1.9. Others
5. Global Adult Vaccines Market Analysis and Forecast, 2021-2031 by Vaccine Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Monovalent
5.1.2. Multivalent
6. Global Adult Vaccines Market Analysis and Forecast, 2021-2031 by Technology (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Live Attenuated Vaccines
6.1.2. Inactivated Viral or Bacterial Vaccines
6.1.3. Toxoid Vaccines
6.1.4. Recombinant Vaccines
6.1.5. Conjugate Vaccines
7. North America Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Adult Vaccines Market Size and Forecast by Vaccine Type
7.3. North America Adult Vaccines Market Size and Forecast by Product Type
7.4. North America Adult Vaccines Market Size and Forecast by Technology
7.5. U.S. Adult Vaccines Market
7.6. Canada Adult Vaccines Market
8. Europe Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Adult Vaccines Market Size and Forecast by Vaccine Type
8.3. Europe Adult Vaccines Market Size and Forecast by Product Type
8.4. Europe Adult Vaccines Market Size and Forecast by Technology
8.5. UK Adult Vaccines Market
8.6. Germany Adult Vaccines Market
8.7. France Adult Vaccines Market
8.8. Rest of Europe Adult Vaccines Market
9. Asia Pacific Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Adult Vaccines Market Size and Forecast by Vaccine Type
9.3. Asia Pacific Adult Vaccines Market Size and Forecast by Product Type
9.4. Asia Pacific Adult Vaccines Market Size and Forecast by Technology
9.5. China Adult Vaccines Market
9.6. India Adult Vaccines Market
9.7. Japan Adult Vaccines Market
9.8. Rest of Asia Pacific Adult Vaccines Market
10. Latin America Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Adult Vaccines Market Size and Forecast by Vaccine Type
10.3. Latin America Adult Vaccines Market Size and Forecast by Product Type
10.4. Latin America Adult Vaccines Market Size and Forecast by Technology
10.4.1. Brazil Adult Vaccines Market
10.4.2. Mexico Adult Vaccines Market
10.4.3. Rest of Latin America Adult Vaccines Market
11. MEA Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Adult Vaccines Market Size and Forecast by Vaccine Type
11.3. MEA Adult Vaccines Market Size and Forecast by Product Type
11.4. MEA Adult Vaccines Market Size and Forecast by Technology
11.5. GCC Adult Vaccines Market
11.6. South Africa Adult Vaccines Market
11.7. Rest of MEA Adult Vaccines Market
12. Companies in the Adult Vaccines Market
12.1. GlaxoSmithKline Plc
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. Sanofi Pasteur
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Pfizer, Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. CSL Limited
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Johnson & Johnson
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Serum Institute of India
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Medimmune
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. AstraZeneca Plc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. BioCSL (Seqirus)
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before
Table 2 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Adult Vaccines Market Drivers & Restraints 2020
Table 7 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 13 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 23 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 33 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 48 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) Before COVID)
Table 68 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96 Recombinant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262 Leading 10 Adult Vaccines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 263 GlaxoSmithKline Plc Profile 2019 (CEO, HQ, Founded, Website)
Table 264 GlaxoSmithKline Plc Adult Vaccines Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 265 GlaxoSmithKline Plc Adult Vaccines Product Offering (Segment, Product Offerings)
Table 266 Merck & Co. Profile 2019 (CEO, HQ, Founded, Website)
Table 267 Merck & Co. Adult Vaccines Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 268 Merck & Co. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 269 Sanofi Pasteur Profile 2019 (CEO, HQ, Founded, Website)
Table 270 Sanofi Pasteur Adult Vaccines Selected Recent Contracts 2017-2019 (Date, Contract Type, Details)
Table 271 Sanofi Pasteur Adult Vaccines Product Offering (Segment, Product Offerings)
Table 272 Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 273 Pfizer, Inc. Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 274 Pfizer, Inc. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 275 Johnson & Johnson Profile 2019 (CEO, HQ, Founded, Website)
Table 276 Johnson & Johnson Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 277 Johnson & Johnson Adult Vaccines Product Offering (Segment, Product Offerings)
Table 281 Serum Institute of India Profile 2019 (CEO, HQ, Founded, Website)
Table 282 Serum Institute of India Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 283 Serum Institute of India Adult Vaccines Product Offering (Segment, Product Offerings)
Table 284 Medimmune Profile 2019 (CEO, HQ, Founded, Website)
Table 285 Medimmune Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 286 Medimmune Adult Vaccines Product Offering (Segment, Product Offerings)
Table 287 AstraZeneca Plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 288 AstraZeneca Plc. Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 289 AstraZeneca Plc. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 290 BioCSL (Seqirus) Profile 2019 (CEO, HQ, Founded, Website)
Table 291 BioCSL (Seqirus) Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 292 BioCSL (Seqirus) Adult Vaccines Product Offering (Segment, Product Offerings)
Table 293 Other Companies Involved in the Adult Vaccines Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Adult Vaccines Market Vaccine Overview
Figure 2 Adult Vaccines Market Vaccine Overview
Figure 3 Adult Vaccines Market Technology Overview
Figure 4 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before
Figure 5 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 6 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 7 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 8 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 9 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 10 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 11 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 12 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 13 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 14 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 15 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 16 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 17 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 18 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 19 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 20 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 21 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 22 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 23 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 24 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 25 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 26 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 27 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 28 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 29 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 30 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 31 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 32 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 33 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 34 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 35 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 36 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 37 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 38 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 39 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 40 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 41 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 42 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 43 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 44 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 45 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 46 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 47 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 48 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 49 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 50 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 51 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 52 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 53 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 54 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 55 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 56 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 57 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 58 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 59 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 60 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 61 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 62 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 63 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 64 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 65 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 66 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 67 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 68 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 69 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) Before COVID)
Figure 70 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 71 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 72 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 73 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 74 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 75 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 76 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 77 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 78 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 79 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 80 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 81 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 82 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 83 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 84 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 85 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 86 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 87 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 88 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 89 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 90 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 91 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 92 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 93 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 94 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 95 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 96 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 97 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 98 Recombinant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 99 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 100 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 101 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 102 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 103 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 104 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 105 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 106 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 107 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 108 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 109 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 110 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 111 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 112 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 113 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 114 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 115 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 116 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 117 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 118 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 119 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 120 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 121 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 122 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 123 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 124 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 125 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 126 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 127 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 128 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 129 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 130 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 131 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 132 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 133 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 134 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 135 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 136 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 137 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 138 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 139 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 140 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 141 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 142 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 143 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 144 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 145 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 146 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 147 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 148 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 149 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 150 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 151 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 152 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 153 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 154 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 155 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 156 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 157 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 158 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 159 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 160 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 161 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 162 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 163 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 164 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 165 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 166 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 167 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 168 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 169 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 170 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 171 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 172 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 173 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 174 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 175 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 176 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 177 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 178 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 179 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 180 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 181 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 182 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 183 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 184 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 185 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 186 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 187 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 188 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 189 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 190 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 191 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 192 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 193 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 194 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 195 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 196 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 197 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 198 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 199 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 200 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 201 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 202 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 203 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 204 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 205 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 206 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 207 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 208 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 209 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 210 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 211 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 212 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 213 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 214 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 215 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 216 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 217 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 218 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 219 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 220 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 221 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 222 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 223 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 224 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 225 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 226 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 227 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 228 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 229 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 230 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 231 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 232 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 233 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 234 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 235 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 236 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 237 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 238 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 239 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 240 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 241 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 242 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 243 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 244 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 245 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 246 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 247 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 248 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 249 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 250 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 251 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 252 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 253 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 254 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 255 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 256 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 257 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 258 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 259 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 260 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 261 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 262 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 263 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Adult Vaccines Market
2.1. Adult Vaccines Market Definition
2.2. Vaccine Submarkets Definitions
2.3. Vaccine Type Submarkets Definitions
2.4. Technology Submarkets Definitions
3. Adult Vaccines Market Overview
3.1. Global Adult Vaccines Market Size and Forecast by Region
3.2. Global Adult Vaccines Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. A rise in Cases of Infectious Diseases in the Adults
3.3.1.2. Increase in Government Funding for Research Activities to Develop Vaccines
3.3.1.3. High Prevalence of Infectious Diseases
3.3.1.4. Rising Focus on Immunization Programs
3.3.1.5. Growing Government Support for Vaccine Development
3.3.1.6. Increasing Company Initiatives to Enhance Vaccine R&D
3.3.2. Market Restraints/Challenges
3.3.2.1. High Cost of Vaccine Development
3.3.2.2. Inadequate Access to Vaccines
3.3.2.3. Product Recalls
3.3.3. Opportunities
3.3.3.1. High Growth Prospects in Emerging Markets
3.3.3.2. Focus on Therapeutic Vaccines
3.3.3.3. Use of Adjuvants in Vaccines
3.3.4. Global Adult Vaccines Market: Trends
3.3.4.1. Increasing Number of Acquisitions
3.3.4.2. Focus on Expanding Capabilities of Current Technologies and Products
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Adult Vaccines Market Analysis and Forecast 2021-2031, by Vaccine (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Influenza
4.1.2. Tetanus/Diphtheria/Pertussis
4.1.3. Varicella
4.1.4. Human Papillomavirus
4.1.5. Zoster
4.1.6. Measles/Mumps/Rubella
4.1.7. Pneumococcal
4.1.8. Hepatitis
4.1.9. Others
5. Global Adult Vaccines Market Analysis and Forecast, 2021-2031 by Vaccine Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Monovalent
5.1.2. Multivalent
6. Global Adult Vaccines Market Analysis and Forecast, 2021-2031 by Technology (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Live Attenuated Vaccines
6.1.2. Inactivated Viral or Bacterial Vaccines
6.1.3. Toxoid Vaccines
6.1.4. Recombinant Vaccines
6.1.5. Conjugate Vaccines
7. North America Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Adult Vaccines Market Size and Forecast by Vaccine Type
7.3. North America Adult Vaccines Market Size and Forecast by Product Type
7.4. North America Adult Vaccines Market Size and Forecast by Technology
7.5. U.S. Adult Vaccines Market
7.6. Canada Adult Vaccines Market
8. Europe Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Adult Vaccines Market Size and Forecast by Vaccine Type
8.3. Europe Adult Vaccines Market Size and Forecast by Product Type
8.4. Europe Adult Vaccines Market Size and Forecast by Technology
8.5. UK Adult Vaccines Market
8.6. Germany Adult Vaccines Market
8.7. France Adult Vaccines Market
8.8. Rest of Europe Adult Vaccines Market
9. Asia Pacific Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Adult Vaccines Market Size and Forecast by Vaccine Type
9.3. Asia Pacific Adult Vaccines Market Size and Forecast by Product Type
9.4. Asia Pacific Adult Vaccines Market Size and Forecast by Technology
9.5. China Adult Vaccines Market
9.6. India Adult Vaccines Market
9.7. Japan Adult Vaccines Market
9.8. Rest of Asia Pacific Adult Vaccines Market
10. Latin America Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Adult Vaccines Market Size and Forecast by Vaccine Type
10.3. Latin America Adult Vaccines Market Size and Forecast by Product Type
10.4. Latin America Adult Vaccines Market Size and Forecast by Technology
10.4.1. Brazil Adult Vaccines Market
10.4.2. Mexico Adult Vaccines Market
10.4.3. Rest of Latin America Adult Vaccines Market
11. MEA Adult Vaccines Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Adult Vaccines Market Size and Forecast by Vaccine Type
11.3. MEA Adult Vaccines Market Size and Forecast by Product Type
11.4. MEA Adult Vaccines Market Size and Forecast by Technology
11.5. GCC Adult Vaccines Market
11.6. South Africa Adult Vaccines Market
11.7. Rest of MEA Adult Vaccines Market
12. Companies in the Adult Vaccines Market
12.1. GlaxoSmithKline Plc
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Merck & Co.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. Sanofi Pasteur
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Pfizer, Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. CSL Limited
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Johnson & Johnson
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Serum Institute of India
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Medimmune
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. AstraZeneca Plc.
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. BioCSL (Seqirus)
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before
Table 2 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Adult Vaccines Market Drivers & Restraints 2020
Table 7 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 13 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 23 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 33 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Table 48 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 58 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 59 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 60 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 61 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 62 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) Before COVID)
Table 68 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96 Recombinant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262 Leading 10 Adult Vaccines Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 263 GlaxoSmithKline Plc Profile 2019 (CEO, HQ, Founded, Website)
Table 264 GlaxoSmithKline Plc Adult Vaccines Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 265 GlaxoSmithKline Plc Adult Vaccines Product Offering (Segment, Product Offerings)
Table 266 Merck & Co. Profile 2019 (CEO, HQ, Founded, Website)
Table 267 Merck & Co. Adult Vaccines Selected Recent Contracts 2019 (Date, Contract Type, Details)
Table 268 Merck & Co. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 269 Sanofi Pasteur Profile 2019 (CEO, HQ, Founded, Website)
Table 270 Sanofi Pasteur Adult Vaccines Selected Recent Contracts 2017-2019 (Date, Contract Type, Details)
Table 271 Sanofi Pasteur Adult Vaccines Product Offering (Segment, Product Offerings)
Table 272 Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 273 Pfizer, Inc. Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 274 Pfizer, Inc. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 275 Johnson & Johnson Profile 2019 (CEO, HQ, Founded, Website)
Table 276 Johnson & Johnson Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 277 Johnson & Johnson Adult Vaccines Product Offering (Segment, Product Offerings)
Table 281 Serum Institute of India Profile 2019 (CEO, HQ, Founded, Website)
Table 282 Serum Institute of India Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 283 Serum Institute of India Adult Vaccines Product Offering (Segment, Product Offerings)
Table 284 Medimmune Profile 2019 (CEO, HQ, Founded, Website)
Table 285 Medimmune Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 286 Medimmune Adult Vaccines Product Offering (Segment, Product Offerings)
Table 287 AstraZeneca Plc. Profile 2019 (CEO, HQ, Founded, Website)
Table 288 AstraZeneca Plc. Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 289 AstraZeneca Plc. Adult Vaccines Product Offering (Segment, Product Offerings)
Table 290 BioCSL (Seqirus) Profile 2019 (CEO, HQ, Founded, Website)
Table 291 BioCSL (Seqirus) Adult Vaccines Selected Recent Contracts 2015-2019 (Date, Contract Type, Details)
Table 292 BioCSL (Seqirus) Adult Vaccines Product Offering (Segment, Product Offerings)
Table 293 Other Companies Involved in the Adult Vaccines Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Adult Vaccines Market Vaccine Overview
Figure 2 Adult Vaccines Market Vaccine Overview
Figure 3 Adult Vaccines Market Technology Overview
Figure 4 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before
Figure 5 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 6 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 7 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 8 Adult Vaccines Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 9 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 10 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 11 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 12 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 13 Adult Vaccines Submarket Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 14 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 15 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 16 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 17 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 18 Influenza Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 19 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 20 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 21 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 22 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 23 Tetanus/Diphtheria/Pertussis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 24 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 25 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 26 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 27 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 28 Varicella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 29 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 30 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 31 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 32 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 33 Human Papillomavirus Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 34 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 35 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 36 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 37 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 38 Zoster Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 39 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 40 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 41 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 42 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 43 Measles/Mumps/Rubella Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 44 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 45 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 46 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 47 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 48 Pneumococcal Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 49 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) before COVID)
Figure 50 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 51 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 52 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 53 Hepatitis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 54 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 55 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 56 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 57 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 58 Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 59 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 60 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 61 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 62 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 63 Adult Vaccines Submarket Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 64 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 65 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 66 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 67 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 68 Monovalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 69 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) Before COVID)
Figure 70 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 71 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 72 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 73 Multivalent Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 74 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 75 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 76 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 77 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 78 Adult Vaccines Market Forecast by Technology 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 79 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 80 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 81 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 82 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 83 Live Attenuated Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 84 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 85 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 86 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 87 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 88 Inactivated Viral or Bacterial Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 89 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 90 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 91 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 92 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 93 Toxoid Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 94 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 95 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 96 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 97 Recombinant Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 98 Recombinant Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 99 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 100 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 101 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 102 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 103 Conjugate Vaccines Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 104 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 105 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 106 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 107 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 108 Regional Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 109 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 110 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 111 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 112 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 113 North America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 114 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 115 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 116 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 117 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 118 North America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 119 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 120 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 121 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 122 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 123 North America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 124 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 125 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 126 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 127 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 128 North America Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 129 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 130 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 131 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 132 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 133 US Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 134 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 135 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 136 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 137 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 138 Canada Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 139 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 140 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 141 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 142 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 143 Europe Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 144 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 145 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 146 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 147 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 148 Europe Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 149 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 150 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 151 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 152 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 153 Europe Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 154 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 155 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 156 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 157 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 158 Europe Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 159 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 160 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 161 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 162 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 163 UK Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 164 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 165 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 166 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 167 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 168 Germany Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 169 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 170 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 171 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 172 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 173 France Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 174 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 175 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 176 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 177 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 178 Rest of Europe Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 179 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 180 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 181 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 182 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 183 Asia Pacific Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 184 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 185 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 186 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 187 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 188 Asia Pacific Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 189 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 190 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 191 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 192 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 193 Asia Pacific Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 194 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 195 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 196 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 197 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 198 Asia Pacific Adult Vaccines Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 199 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 200 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 201 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 202 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 203 China Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 204 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 205 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 206 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 207 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 208 India Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 209 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 210 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 211 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 212 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 213 Japan Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 214 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 215 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 216 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 217 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 218 RoAPAC Adult Vaccines Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 219 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 220 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 221 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 222 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 223 Middle East Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 224 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 225 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 226 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 227 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 228 Middle East Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 229 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 230 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 231 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 232 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 233 Middle East Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 234 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 235 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 236 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 237 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 238 Latin America Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 239 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 240 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 241 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 242 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 243 Latin America Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 244 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 245 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 246 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 247 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 248 Latin America Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 249 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 250 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 251 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 252 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 253 Africa Adult Vaccines Market Forecast by Vaccine Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 254 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 255 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 256 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 257 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 258 Africa Adult Vaccines Market Forecast by Vaccine 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 259 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 260 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 261 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 262 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 263 Africa Adult Vaccines Market Forecast by Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Companies Profiled in the Report
1. GlaxoSmithKline Plc
2. Merck & Co.
3. Sanofi Pasteur
4. Pfizer, Inc.
5. CSL Limited
6. Johnson & Johnson
7. Serum Institute of India
8. Medimmune
9. AstraZeneca Plc.
10. BioCSL (Seqirus)
List of Companies Mentioned in the Report:
1. AbbVie
2. Alexion
3. ALK-Abello
4. Allergan
5. Almirall
6. Amgen
7. Astellas
8. AstraZeneca
9. Baxter
10. Bayer
11. Biogen Idec
12. Bristol-Myers Squibb
13. Celgene
14. CSL
15. Daiichi Sankyo
16. Eisai
17. Endo
18. Gilead Sciences
19. GlaxoSmithKline
20. Incyte
21. Jazz
22. Johnson & Johnson
23. Kyowa Hakko Kirin
24. Lilly
25. Lundbeck
26. Mallinckrodt
27. Merck & Co.
28. Merck KGaA
29. Mitsubishi Tanabe Pharma
30. Mochida
31. Nippon Shinyaku
32. Novartis
33. Novo Nordisk
34. Ono
35. Otsuka
36. Pfizer
37. Recordati
38. Regeneron
39. Roche
40. Sanofi
41. Santen
42. Sawai
43. Shionogi
44. Shire
45. Sumitomo Dainippon
46. Takeda
47. Teva
48. UCB
49. United Therapeutics
50. Valeant
51. Vertex
52. Wockhardt
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
1. GlaxoSmithKline Plc
2. Merck & Co.
3. Sanofi Pasteur
4. Pfizer, Inc.
5. CSL Limited
6. Johnson & Johnson
7. Serum Institute of India
8. Medimmune
9. AstraZeneca Plc.
10. BioCSL (Seqirus)
List of Companies Mentioned in the Report:
1. AbbVie
2. Alexion
3. ALK-Abello
4. Allergan
5. Almirall
6. Amgen
7. Astellas
8. AstraZeneca
9. Baxter
10. Bayer
11. Biogen Idec
12. Bristol-Myers Squibb
13. Celgene
14. CSL
15. Daiichi Sankyo
16. Eisai
17. Endo
18. Gilead Sciences
19. GlaxoSmithKline
20. Incyte
21. Jazz
22. Johnson & Johnson
23. Kyowa Hakko Kirin
24. Lilly
25. Lundbeck
26. Mallinckrodt
27. Merck & Co.
28. Merck KGaA
29. Mitsubishi Tanabe Pharma
30. Mochida
31. Nippon Shinyaku
32. Novartis
33. Novo Nordisk
34. Ono
35. Otsuka
36. Pfizer
37. Recordati
38. Regeneron
39. Roche
40. Sanofi
41. Santen
42. Sawai
43. Shionogi
44. Shire
45. Sumitomo Dainippon
46. Takeda
47. Teva
48. UCB
49. United Therapeutics
50. Valeant
51. Vertex
52. Wockhardt
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
Download sample pages
Complete the form below to download your free sample pages for Adult Vaccines Market Report to 2031Related reports
Veterinary Vaccines Market Report 2022-2032
The increased frequency of zoonotic illnesses, activities by different government agencies and animal groups to protect animal health, and the...Full DetailsPublished: 28 February 2022mRNA Vaccines Market Report 2021-2031
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative...Full DetailsPublished: 01 October 2020Meningococcal Vaccines Market Report 2021-2031
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is...Full DetailsPublished: 30 September 2021Animal Health Market Report 2021-2031
The animal health sector is anticipated to evolve at a rapid pace. The veterinary health industry has diverse opportunities to...Full DetailsPublished: 28 January 2021Veterinary Services Market Report 2021-2031
Where the Veterinary Services market is heading? If you are involved in this industry you must read this newly updated...
Full DetailsPublished: 01 January 1970Vaccine Delivery Devices Market Report 2021-2031
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product...Full DetailsPublished: 06 January 2021Veterinary Therapeutics Market Report 2021-2031
Where the Veterinary Therapeutics is market heading? If you are involved in this sector you must read this newly updated...Full DetailsPublished: 01 January 1970Vaccine Adjuvants Market Report 2021-2031
The opportunity for innovation within the vaccine adjuvants market remains strong. As time progresses, the technology used in the manufacturing...Full DetailsPublished: 02 February 2021Inactivated Vaccines Market Report 2020-2030
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine...
Full DetailsPublished: 13 May 2021Animal Vaccine Market Report to 2031
Where is the Animal Vaccines market heading? If you are involved in this sector you must read this newly updated...Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Adult Vaccines Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033
The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.
03 October 2023
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
